How to Compare GTM Performance Across a Portfolio When Every Company Speaks a Different Revenue Language
I want to be direct about where I'm coming from before you read this: my background is founder-side SaaS sales, not PE operations. But the problem I'm describing here — GTM data that can't be compared across companies because every team built their process in isolation — is one I've watched play out at the company level dozens of times. Operating partners are dealing with the same problem at scale. That's the lens I'm writing from.
More than 18,000 portfolio companies are stuck beyond traditional hold periods. LPs are asking harder questions about value creation. And GTM — the function most responsible for revenue — is still the least instrumented and least comparable capability across most portfolios.
Every portco has a different CRM configuration. A different definition of a qualified opportunity. A different story for why the pipeline number means what it means.
That's not a data problem. It's a governance problem.
The Root Cause: No Common Language
I've seen this at the company level: one team calls anything with a signed NDA a qualified lead. Another requires a scoped proposal before moving a deal to the same stage. A third tracks ARR in a spreadsheet that lives in the CFO's inbox.
When you try to compare pipeline health or conversion efficiency across those three companies, you're not comparing data — you're comparing opinions.
This isn't a criticism of portco leadership. It's a predictable outcome of building companies in isolation. The problem surfaces when you need to answer a board question about where commercial risk is concentrated.
Why 100-Day Plans Don't Fix This
The instinct is to install a new CRM, hire a VP of Sales, or launch a campaign. I understand the instinct — when you're under pressure to show progress, visible action feels like progress.
But none of those moves produce comparable data at the portfolio level. And none of them surface the actual constraint — which might be ICP definition, pricing architecture, or a sales motion misaligned with how the buyer actually makes decisions.
Acceleration before diagnosis is how you burn runway on the wrong lever. I've watched it happen. The new VP of Sales inherits a pipeline full of deals that were never real, hits the ground running, and six months later the board is asking why nothing closed.
What Comparability Actually Requires
I'll be honest: I don't have a portfolio-wide solution that I've personally deployed across dozens of holdings. What I do have is a framework we've built at Andru for diagnosing GTM readiness at the company level — and a hypothesis about how that scales to portfolio comparability. Take the portfolio-level claims as directional, not proven.
Here's what I think it requires:
A shared diagnostic instrument. Before you can compare performance, you need a common assessment framework applied consistently across holdings — one that scores commercial readiness against the same criteria regardless of company size, sector, or CRM vendor. At Andru, we call this a Revenue Readiness assessment. It produces a scored output you can bring into a portfolio review. Whether it's our tool or something you build internally, the principle is the same: you need a rubric, not a narrative.
Standardized ICP definitions. The single most common source of pipeline inflation I've seen is an undefined or inconsistently applied Ideal Customer Profile. When every company defines its target customer differently, win-rate comparisons are meaningless and churn attribution is guesswork. A common schema for ICP documentation — even if the underlying profiles differ by vertical — gives you a foundation for comparing commercial efficiency.
A value-creation roadmap that names the mechanism. 'Grow revenue' is not a plan. A defensible roadmap names the specific commercial bottleneck, the intervention, the leading indicator that confirms the intervention is working, and the timeline. That structure makes it possible to compare progress across holdings without requiring a bespoke narrative from each CEO.
The AI Question
Funds are building AI capability at the platform level. Most portcos are not yet instrumented to benefit from it. If your portcos can't produce clean, comparable GTM data today, AI tooling at the fund level will analyze noise, not signal.
Comparability is the prerequisite for AI leverage, not the output of it. That's not a sales pitch — it's a sequencing problem.
Three Moves, In Order
Run a diagnostic before you prescribe. Apply a structured assessment to every holding before the 100-day plan is written. Score ICP clarity, pipeline stage integrity, conversion visibility, and retention instrumentation on a common rubric. The output tells you where commercial risk is concentrated and what type of intervention is warranted.
Standardize the schema, not the stack. You can't force every portco onto the same CRM. You can require that every portco maps its existing stages to a common definitional schema — so that 'Stage 3' at Company A and 'Proposal Sent' at Company B mean the same thing in your portfolio dashboard. This is a governance decision, not a technology project.
Make GTM artifacts portable. ICP definitions, persona libraries, and value-creation roadmaps should be documented in a format that survives leadership turnover and travels into board packages without translation. If the commercial strategy lives only in the head of the current VP of Sales, it's not an operating asset — it's a retention risk.
I'm building tools that help founders do this at the company level. If you're an operating partner thinking about the portfolio-level version of this problem, I'd genuinely like to understand where the framework breaks down at your scale. That's not a sales opener — it's where I'd learn something.